Why Are Biofrontera Shares Surging Today?

The United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Inc BFRI titled "Illumination for Photodynamic Therapy." The patent covers pain-reducing illumination protocol for photodynamic therapy (PDT).

• The patent also strengthens Biofrontera's competitiveness for its FDA-approved combination product, Ameluz, with PDT-lamp BF-RhodoLED and its successor model RhodoLED XL.
• The protocol consists of changing illumination intensities combined in a predefined order with interruptions of the illumination to modulate and reduce pain perception. 
• The new illumination protocol aims at combining the high efficacy of Ameluz with the flexibility of BF-RhodoLED to modulate light for pain reduction.
• Biofrontera will start a Phase 3 trial to treat actinic keratoses on the face and scalp with 3 tubes of Ameluz and the RhodoLED XL lamp involving the new protocol in 2022.
• Price Action: BFRI shares 32.1% at $5.72 during the market session on the last check Thursday.